BioCentury | Apr 25, 2019
Company News

Salix licenses S1P receptor modulator from Mitsubishi

...Companies Inc. (TSX:BHC; NYSE:BHC). Mary Romeo, Staff Writer amiselimod (MT-1303) Plenvu (NER1006) Bausch Health Companies Inc. Biogen Inc. Mitsubishi Tanabe Pharma Corp. Norgine B.V. Salix...
BioCentury | Mar 15, 2019
Clinical News

Shield's oral Feraccru non-inferior to IV Injectafer in Phase IIIb

...Feraccru is under FDA review for the same indication; its PDUFA date is July 27. Norgine B.V....
...million) development milestone payment from Norgine following the AEGIS-H2H readout. Mark Zipkin, Staff Writer Feraccru, ferric maltol (ST10) Norgine B.V. Shield...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Neurology

...has the compound in Phase III testing to treat asthma. Novartis AG, Allergan plc and Norgine B.V....
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...PIVOT-02 June Neurocrine Biosciences Inc. (NASDAQ:NBIX) / AbbVie Inc. (NYSE:ABBV) Elagolix Endometriosis PDUFA date 2Q18 Norgine B.V....
BioCentury | Feb 16, 2018
Clinical News

FDA prolongs review of Valeant's bowel cleansing agent

...The Salix Pharmaceuticals Ltd. subsidiary of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) and partner Norgine B.V. (Amsterdam...
...Canadian rights to develop and commercialize Plenvu from Norgine (see BioCentury, Aug. 22, 2016 ). Norgine B.V....
...Netherlands Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Product: Plenvu (NER1006) Business: Gastrointestinal Elizabeth S. Eaton NER1006 Plenvu Norgine B.V. Valeant...
BioCentury | Sep 14, 2017
Company News

Management tracks: SymCel, Taro, Akcea

...NASDAQ:IPCI) named Andrew Patient CFO. He was CFO at Merus Labs International Inc. , which Norgine B.V....
...Inc. Akcea Therapeutics Inc. Artios Pharma Ltd. AstraZeneca plc Biogen Inc. BioLamina AB Eyevensys S.A.S. Intellipharmaceutics International Inc. Kane Biotech Inc. Merus Labs International Inc. Norgine B.V. Rugen...
BioCentury | Dec 2, 2016
Company News

Navidea, Cardinal Health deal

...the oral cavity, breast cancer or melanoma. It is also approved in the EU, where Norgine B.V....
BioCentury | Nov 15, 2016
Clinical News

Plenvu: Ph III data

...citrate in adenoma and polyp detection rates in both the overall colon and ascending colon. Norgine...
...and Canadian rights to develop and commercialize Plenvu from Norgine (see BioCentury, Aug. 22 ). Norgine B.V....
...and polyp detection rates in the overall and ascending colon and safety Milestone: NA Jaime De Leon NER1006 Norgine B.V. Valeant...
BioCentury | Aug 22, 2016
Company News

Norgine, Valeant Pharmaceuticals deal

...and commercialize NER1006 , an osmotic low-volume polyethylene glycol laxative, in the U.S. and Canada. Norgine...
...to Valeant. NER1006 has completed Phase III trials in bowel cleansing prior to colonoscopy, and Norgine...
...to submit an NDA this year to FDA. The companies declined to disclose financial terms. Norgine B.V....
BioCentury | Jul 11, 2016
Clinical News

NER1006: Phase III data

...of the ascending colon. Data were presented at Digestive Disease Week meeting in San Diego. Norgine B.V....
Items per page:
1 - 10 of 81
BioCentury | Apr 25, 2019
Company News

Salix licenses S1P receptor modulator from Mitsubishi

...Companies Inc. (TSX:BHC; NYSE:BHC). Mary Romeo, Staff Writer amiselimod (MT-1303) Plenvu (NER1006) Bausch Health Companies Inc. Biogen Inc. Mitsubishi Tanabe Pharma Corp. Norgine B.V. Salix...
BioCentury | Mar 15, 2019
Clinical News

Shield's oral Feraccru non-inferior to IV Injectafer in Phase IIIb

...Feraccru is under FDA review for the same indication; its PDUFA date is July 27. Norgine B.V....
...million) development milestone payment from Norgine following the AEGIS-H2H readout. Mark Zipkin, Staff Writer Feraccru, ferric maltol (ST10) Norgine B.V. Shield...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Neurology

...has the compound in Phase III testing to treat asthma. Novartis AG, Allergan plc and Norgine B.V....
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...PIVOT-02 June Neurocrine Biosciences Inc. (NASDAQ:NBIX) / AbbVie Inc. (NYSE:ABBV) Elagolix Endometriosis PDUFA date 2Q18 Norgine B.V....
BioCentury | Feb 16, 2018
Clinical News

FDA prolongs review of Valeant's bowel cleansing agent

...The Salix Pharmaceuticals Ltd. subsidiary of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) and partner Norgine B.V. (Amsterdam...
...Canadian rights to develop and commercialize Plenvu from Norgine (see BioCentury, Aug. 22, 2016 ). Norgine B.V....
...Netherlands Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Laval, Quebec Product: Plenvu (NER1006) Business: Gastrointestinal Elizabeth S. Eaton NER1006 Plenvu Norgine B.V. Valeant...
BioCentury | Sep 14, 2017
Company News

Management tracks: SymCel, Taro, Akcea

...NASDAQ:IPCI) named Andrew Patient CFO. He was CFO at Merus Labs International Inc. , which Norgine B.V....
...Inc. Akcea Therapeutics Inc. Artios Pharma Ltd. AstraZeneca plc Biogen Inc. BioLamina AB Eyevensys S.A.S. Intellipharmaceutics International Inc. Kane Biotech Inc. Merus Labs International Inc. Norgine B.V. Rugen...
BioCentury | Dec 2, 2016
Company News

Navidea, Cardinal Health deal

...the oral cavity, breast cancer or melanoma. It is also approved in the EU, where Norgine B.V....
BioCentury | Nov 15, 2016
Clinical News

Plenvu: Ph III data

...citrate in adenoma and polyp detection rates in both the overall colon and ascending colon. Norgine...
...and Canadian rights to develop and commercialize Plenvu from Norgine (see BioCentury, Aug. 22 ). Norgine B.V....
...and polyp detection rates in the overall and ascending colon and safety Milestone: NA Jaime De Leon NER1006 Norgine B.V. Valeant...
BioCentury | Aug 22, 2016
Company News

Norgine, Valeant Pharmaceuticals deal

...and commercialize NER1006 , an osmotic low-volume polyethylene glycol laxative, in the U.S. and Canada. Norgine...
...to Valeant. NER1006 has completed Phase III trials in bowel cleansing prior to colonoscopy, and Norgine...
...to submit an NDA this year to FDA. The companies declined to disclose financial terms. Norgine B.V....
BioCentury | Jul 11, 2016
Clinical News

NER1006: Phase III data

...of the ascending colon. Data were presented at Digestive Disease Week meeting in San Diego. Norgine B.V....
Items per page:
1 - 10 of 81